ANCA-Associated Vasculitis Treatment in 2022 - Prof. Jayne (Cambridge)

Professor David Jayne discusses current standards of diagnosis and treatment of ANCA-associated Vasculitis (AAV). Professor David Jayne is Co-Author of the KDIGO 2021 Clinical Practice Guidelines for the management of glomerular diseases; he has designed and conducted many landmark trials in the field of AAV. The interview was recorded on April 1st, 2022. Moderators: Prof. Dr. Kirsten de Groot (Offenbach, Germany), Priv.-Doz. Dr. Andreas Kronbichler (Cambridge, UK / Innsbruck, Austria) and Prof. Dr. Gunnar Heine (Frankfurt, Germany). Articles discussed: Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. de Groot K et al Ann Intern Med. 2009 doi: 10.7326/0003-4819-150-10-200905190-00004. Avacopan for the Treatment of ANCA-Associated Vasculitis. Jayne DRW et al N Engl J Med 2021 doi: 10.1056/NEJMoa2023386 Retracted June 29th 2026 https://pubmed.ncbi.nlm.nih.gov/42377... Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Karras A, …, Jayne D Ann Rheum Dis. 2017 doi: 10.1136/annrheumdis-2017-211123 Recommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseases. Wijetilleka S, Jayne DR et al. Rheumatology (Oxford). 2019 doi: 10.1093/rheumatology/key394. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. Guillevin L et al.; French Vasculitis Study Group. N Engl J Med. 2014 doi: 10.1056/NEJMoa1404231. Rituximab Associated Hypogammaglobulinemia in Autoimmune Disease. Tieu J, … , Jayne DRW. Front Immunol. 2021 doi: 10.3389/fimmu.2021.671503 Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Tervaert JW et al. Lancet. 1990 doi: 10.1016/0140-6736(90)92205-v. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Gopaluni S, …, Jayne DR Trials. 2017 doi: 10.1186/s13063-017-1857-z. The effects of plasma exchange in patients with ANCA-associated vasculitis: an updated systematic review and meta-analysis. Walsh M, ..., Jayne DRW BMJ. 2022 doi: 10.1136/bmj-2021-064604. Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis. Sethi S et al. Nephrol Dial Transplant. 2017 doi: 10.1093/ndt/gfw299 Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. De Groot K, …, Jayne DR. Arthritis Rheum. 2005 doi: 10.1002/art.21142 Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Smith RM, …, Jayne D; RITAZAREM co-investigators. Ann Rheum Dis. 2020 doi: 10.1136/annrheumdis-2019-216863 EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Yates M, ..., Jayne DR, Mukhtyar C. Ann Rheum Dis. 2016 doi: 10.1136/annrheumdis-2016-209133. Mycophenolate mofetil versus cyclophosphamide for remission induction in ANCA-associated vasculitis: a randomised, non-inferiority trial. Jones RB, …, Jayne D. Ann Rheum Dis. 2019 doi: 10.1136/annrheumdis-2018-214245. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. Jones RB,..., Jayne DR N Engl J Med 2010 doi: 10.1056/NEJMoa0909169. Plasma exchange and glucocorticoid dosing for patients with ANCA-associated vasculitis: a clinical practice guideline. Zeng L et al. BMJ 2022 doi: 10.1136/bmj-2021-064597 PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab. van Dam LS et al. Nephrol Dial Transplant 2021 doi: 10.1093/ndt/gfaa066 Rituximab versus cyclophosphamide for ANCA-associated vasculitis. Stone JH et al. N Engl J Med 2010 doi: 10.1056/NEJMoa0909905. Clinical outcomes of treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis based on ANCA type. Unizony S et al. Ann Rheum Dis 2016 doi: 10.1136/annrheumdis-2015-208073 Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Jones RB,…, Jayne DR Ann Rheum Dis 2015 doi: 10.1136/annrheumdis-2014-206404. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. Walsh M et al. N Engl J Med 2020 doi: 10.1056/NEJMoa1803537. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. Jayne DR et al. J Am Soc Nephrol 2007 doi: 10.1681/ASN.2007010090 KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int 2021 doi: 10.1016/j.kint.2021.05.021. Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Bossuyt X et al. Nat Rev Rheumatol 2017 doi: 10.1038/nrrheum.2017.140